Samer S. Kasbari

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler et al. · Journal of Clinical Oncology · 2020 · 240 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.

Randall E. Harris, Samer S. Kasbari, William B. Farrar · Oncology Reports · 1999 · 174 citations

Medicine, Oncology, Pharmacology +9

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Heather A. Wakelee, Suzanne E. Dahlberg, Steven M. Keller et al. · The Lancet Oncology · 2017 · 172 citations · Full text

Medicine, Oncology, Pharmacology +14

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

Multicenter, randomized, double‐blind phase 2 trial of <scp>FOLFIRI</scp> with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova et al. · Cancer · 2018 · 37 citations · Full text

Medicine, Oncology, Pharmacology +12